Background and Aims: Patients in whom neutropenia recovery is complicated by pneumonia have an increased risk of acute lung injury (ALI) and detrimental outcomes. The aim of the present study was to investigate whether inhibition of neutrophil elastase (NE) is effective in lipopolysaccharide (LPS)-induced ALI during neutropenia recovery in a murine model, and whether it upregulates the activation of the MerTK signalling pathway.
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Methods: Cyclophosphamide was given to mice to induce neutropenia. Seven days later, they were administered LPS by intratracheal instillation. Sivelestat, a neutrophil elastase inhibitor, was given by intraperitoneal injection once daily starting on day 0 and continuing until mice were sacrificed on day 5 (preventive group). Alternatively, sivelestat was given after, instead of before, LPS administration on day 2 (therapeutic group).
Results: Sivelestat attenuated the lung oedema and histopathological changes associated with LPS-induced lung injury. The accumulation of neutrophils and the concentrations of TNF-α, IL-6, and MPO in bronchoalveolar lavage (BAL) fluids were inhibited effectively by sivelestat. The expression of ICAM-1 and NF-κB p65 was also reduced after sivelestat administration. The protein and gene expression of MerTK tended to increase with sivelestat treatment.
Conclusion:
Sivelestat significantly attenuated LPS induced ALI during recovery from neutropenia, and this effect was associated with MerTK induction. These findings suggest that NE inhibition could be a promising means of alleviating lung inflammation without increasing susceptibility to infection in ALI/ARDS during neutropenia recovery. Background and Aims: Autophagy is a highly conserved selfdegradative process which balance sources of energy in many physiological conditions. Chronic obstructive pulmonary disease (COPD) is a progressive life-threatening disease caused mainly by cigarette smoking.
LABA/LAMA combination significantly ameliorate the decline in lung function in patient with COPD. Recently, several evidences suggest that increased autophagy contributes to COPD pathogenesis. Moreover, the effect of muscarinic receptor antagonists and β2-agonists on regulating autophagy have been documented. We hypothesis that autophagy may be a potential novel target for dual bronchodilator treatment in an in vitro model that mimics COPD.
Methods: BEAS-2B human bronchial epithelial cells were pre-treated with olodaterol/tiotropium or indacaterol/glycopyrrolate followed by exposure to cigarette smoke extract for 6 h. Autophagy was determined by flow cytometry, acridine orange staining and western blot. MTT assay, Annexin V assay and propidium iodide staining were used to evaluate cell death, apoptosis and cell cycle arrest. Oxidative stress were performed by flow cytometry, DCFDA staining. Statistical analyses were performed using GraphPad Prism. P-values ≤ 0.05 were considered significant.
Results: Olodaterol/tiotropium or indacaterol/glycopyrrolate treatment decreased formation of AVO (lysosomes and autophagolysosomes), the ratio of LC3-II/LC3-I and Beclin1 expression without affecting apoptosis and cell cycle progression in BEAS-2B cells stimulated with CSE. Moreover, olodaterol/tiotropium and indacaterol/glycopyrrolate treatment reversed CSE-induced cell death, respectively. Oxidative stress is a major inducer of autophagy. In our finding, olodaterol/tiotropium and indacaterol/ glycopyrrolate both decrease intracellular ROS level in BEAS-2B cells stimulated with CSE. In comparison, indacaterol/glycopyrrolate combination has a stronger inhibitory effect on autophagy and oxidative stress than olodaterol/tiotropium.
These data provide a novel evidence that dual bronchodilator retards bronchial epithelial cells death through regulating autophagy via inhibiting oxidative stress in BEAS-2B cells stimulated with CSE, which suggest that autophagy may be a potential novel mechanism of the action of dual bronchodilator treatment in COPD. 
